TIGIT:CD155/CD112 immune inhibition (in green)

We previously addressed the PD-1:PD-L1/PD-L2 immune inhibition and the corresponding cell-based tools to screen immuno-oncology agents for restoring antitumor immune response. Unfortunately cancer cells have other ways to escape and survive. Let’s look together at another immune inhibition pathway, namely the TIGIT:CD155/CD112.

The HiP™ (High Purity) distinction by BPS Bioscience starts, of course (as the name says), with a high purity level. But that’s not enough. Such pure proteins may aggregate, which is not compatible with binding assays. Thus, the HiP™ label also demands a low level of aggregation, or even none at all.